BioRestorative Therapies
-
Biologics
BioRestorative Therapies Announces Activation of Northwell Health in the Company’s Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
–Site activation allows for patients in the State of New York to participate in the BRTX-100 trial— –15 Clinical Sites Identified, 12…
Read More » -
Biologics
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering
MELVILLE, N.Y., July 11, 2023 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage…
Read More » -
Biologics
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
—Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100– MELVILLE,…
Read More » -
Biologics
BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing
–License will enable expanded clinical operations for investigator-initiated trials and potential “right to try” uses of BRTX-100.— MELVILLE, N.Y., May 31,…
Read More » -
Biologics
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
— Intellectual Property Provides a Cell-Based Therapeutic Platform Designed to Target All Avascular Zones— MELVILLE, N.Y., Dec. 05, 2022 (GLOBE NEWSWIRE)…
Read More » -
Biologics
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:…
Read More » -
Biologics
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused…
Read More » -
Biologics
BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
— First Site Will Enroll First Patient in the Clinical Study– MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies,…
Read More » -
Spine
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
MELVILLE, N.Y.,, April 18, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage…
Read More » -
Biologics
BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program
Notice of Allowance Grants Protection for BioRestorative’s Phase 2 Clinical Program to Treat Chronic Lumbar Disc Disease MELVILLE, N.Y., Feb.…
Read More » -
Biologics
BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance
MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:BRTX), a life sciences company…
Read More » -
Spine
BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:BRTX), a life sciences company…
Read More » -
Biologics
BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer
MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company”) (NASDAQ:BRTX), a life sciences company focused on…
Read More » -
Financial
BioRestorative Therapies Announces Closing of $23 Million Public Offering
MELVILLE, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company”) (NASDAQ:BRTX), a life sciences company focused on…
Read More » -
Biologics
BioRestorative Therapies Awarded One of Top 10 Spine Device Companies by MedTech Outlook
MELVILLE, N.Y., Aug. 19, 2021 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences…
Read More »